loading
Schlusskurs vom Vortag:
$4.55
Offen:
$4.55
24-Stunden-Volumen:
853.18K
Relative Volume:
0.62
Marktkapitalisierung:
$388.18M
Einnahmen:
$20.65M
Nettoeinkommen (Verlust:
$-192.65M
KGV:
-1.4511
EPS:
-3.17
Netto-Cashflow:
$-134.39M
1W Leistung:
-14.41%
1M Leistung:
-17.03%
6M Leistung:
-16.88%
1J Leistung:
-59.75%
1-Tages-Spanne:
Value
$4.44
$4.69
1-Wochen-Bereich:
Value
$4.44
$5.44
52-Wochen-Spanne:
Value
$4.305
$19.34

Verve Therapeutics Inc Stock (VERV) Company Profile

Name
Firmenname
Verve Therapeutics Inc
Name
Telefon
(978) 501-3026
Name
Adresse
201 BROOKLINE AVENUE, BOSTON
Name
Mitarbeiter
255
Name
Twitter
Name
Nächster Verdiensttermin
Name
Neueste SEC-Einreichungen
Name
VERV's Discussions on Twitter

Vergleichen Sie VERV mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
VERV 4.605 388.18M 20.65M -192.65M -134.39M -3.17
VRTX 449.83 115.43B 10.63B -479.80M -1.35B 13.33
REGN 746.11 82.04B 13.85B 4.65B 3.32B 35.06
ARGX 594.70 35.30B 1.86B -40.29M -1.28B -4.16
ALNY 245.75 32.04B 2.09B -332.26M 16.06M -4.14
BNTX 107.87 24.89B 3.30B -501.07M 1.03B 11.54

Verve Therapeutics Inc Stock (VERV) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2023-04-13 Eingeleitet Canaccord Genuity Buy
2023-02-01 Eingeleitet Cantor Fitzgerald Neutral
2022-12-15 Eingeleitet Goldman Sell
2022-10-06 Eingeleitet Credit Suisse Neutral
2022-08-25 Hochstufung Stifel Hold → Buy
2022-06-17 Eingeleitet BMO Capital Markets Outperform
2022-02-18 Eingeleitet RBC Capital Mkts Outperform
2021-09-24 Eingeleitet Stifel Hold
2021-07-12 Eingeleitet Guggenheim Buy
2021-07-12 Eingeleitet JP Morgan Neutral
2021-07-12 Eingeleitet Jefferies Buy
2021-07-12 Eingeleitet William Blair Outperform
Alle ansehen

Verve Therapeutics Inc Aktie (VERV) Neueste Nachrichten

pulisher
Nov 14, 2024

FY2024 EPS Forecast for Verve Therapeutics Raised by Analyst - MarketBeat

Nov 14, 2024
pulisher
Nov 13, 2024

Verve Therapeutics' SWOT analysis: gene editing firm's stock faces hurdles - Investing.com India

Nov 13, 2024
pulisher
Nov 13, 2024

Verve Therapeutics' SWOT analysis: gene editing firm's stock faces hurdles By Investing.com - Investing.com UK

Nov 13, 2024
pulisher
Nov 08, 2024

(VERV) On The My Stocks Page - Stock Traders Daily

Nov 08, 2024
pulisher
Nov 08, 2024

What is William Blair's Forecast for VERV FY2024 Earnings? - MarketBeat

Nov 08, 2024
pulisher
Nov 08, 2024

FY2024 Earnings Forecast for VERV Issued By Lifesci Capital - MarketBeat

Nov 08, 2024
pulisher
Nov 08, 2024

HC Wainwright Cuts Earnings Estimates for Verve Therapeutics - MarketBeat

Nov 08, 2024
pulisher
Nov 06, 2024

Analyst Scoreboard: 4 Ratings For Verve Therapeutics - Benzinga

Nov 06, 2024
pulisher
Nov 06, 2024

Verve Therapeutics (NASDAQ:VERV) Price Target Lowered to $14.00 at HC Wainwright - MarketBeat

Nov 06, 2024
pulisher
Nov 06, 2024

Verve Therapeutics price target raised to $32 from $29 at Canaccord - TipRanks

Nov 06, 2024
pulisher
Nov 06, 2024

Verve Therapeutics Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance

Nov 06, 2024
pulisher
Nov 06, 2024

VERVE Therapeutics stock target cut, keeps buy on trial updates By Investing.com - Investing.com UK

Nov 06, 2024
pulisher
Nov 06, 2024

Verve Therapeutics price target lowered to $14 from $15 at H.C. Wainwright - TipRanks

Nov 06, 2024
pulisher
Nov 05, 2024

Verve Therapeutics Reports Q3 Progress and Financials - TipRanks

Nov 05, 2024
pulisher
Nov 05, 2024

Verve Therapeutics (VERV) Reports Q3 Loss, Tops Revenue Estimates - MSN

Nov 05, 2024
pulisher
Nov 05, 2024

Verve Therapeutics earnings beat by $0.09, revenue topped estimates - Investing.com Canada

Nov 05, 2024
pulisher
Nov 05, 2024

Verve Therapeutics (NASDAQ:VERV) Trading Up 10.1%Here's What Happened - MarketBeat

Nov 05, 2024
pulisher
Nov 05, 2024

Verve Therapeutics reports Q3 EPS (59c), consensus (70c) - TipRanks

Nov 05, 2024
pulisher
Nov 05, 2024

Verve Therapeutics: Q3 Earnings Snapshot - Marketscreener.com

Nov 05, 2024
pulisher
Nov 05, 2024

Verve Therapeutics Announces Pipeline Progress and Reports Third Quarter 2024 Financial Results - GlobeNewswire

Nov 05, 2024
pulisher
Nov 05, 2024

Vanguard Group Inc's Strategic Reduction in Verve Therapeutics I - GuruFocus.com

Nov 05, 2024
pulisher
Nov 01, 2024

Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Nov 01, 2024
pulisher
Nov 01, 2024

VERV Deadline: VERV Investors Have Opportunity to Lead Verve The - GuruFocus.com

Nov 01, 2024
pulisher
Oct 29, 2024

VERV Investors Have Opportunity to Lead Verve Therapeutics, Inc. - GuruFocus.com

Oct 29, 2024
pulisher
Oct 28, 2024

Deadline coming up on Oct. 28th in Lawsuit for Investors who lost - openPR

Oct 28, 2024
pulisher
Oct 28, 2024

Investors who lost money on Verve Therapeutics, Inc.(VERV) should contact Levi & Korsinsky about pending Class ActionVERV - AccessWire

Oct 28, 2024
pulisher
Oct 28, 2024

VERV LAWSUIT ALERT: Levi & Korsinsky Notifies Verve Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - AccessWire

Oct 28, 2024
pulisher
Oct 28, 2024

VERV Investors Have Opportunity to Lead Verve Therapeutics, Inc. Securities Fraud Lawsuit Filed by the Schall Law Firm - PR Newswire

Oct 28, 2024
pulisher
Oct 28, 2024

FINAL VERV DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Verve Therapeutics, Inc. Investors to Join the Class Action Lawsuit! - AccessWire

Oct 28, 2024
pulisher
Oct 28, 2024

Verve Therapeutics, Inc. Sued for Securities Law ViolationsContact The Gross Law Firm Before October 28, 2024 to Discuss Your RightsVERV - cnhinews.com

Oct 28, 2024
pulisher
Oct 27, 2024

VERV DEADLINE TOMORROW: ROSEN, A LEADING LAW FIRM, - GlobeNewswire

Oct 27, 2024
pulisher
Oct 27, 2024

VERV DEADLINE TOMORROW: ROSEN, A LEADING LAW FIRM, Encourages Verve Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – VERV - ForexTV.com

Oct 27, 2024
pulisher
Oct 27, 2024

FINAL REMINDER VERV DEADLINE: Bronstein, Gewirtz & Grossman LLC Alerts Verve Therapeutics, Inc. Investors to Participate in the Class Action Lawsuit! - AccessWire

Oct 27, 2024
pulisher
Oct 26, 2024

VERV Deadline: Rosen Law Firm Encourages Verve Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important October 28 Deadline in Securities Class Action Commenced by the Firm – VERV - Business Wire

Oct 26, 2024
pulisher
Oct 25, 2024

SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Verve Therapeutics, Inc.VERV - cnhinews.com

Oct 25, 2024
pulisher
Oct 25, 2024

SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Verve Therapeutics - PR Newswire

Oct 25, 2024
pulisher
Oct 24, 2024

VERV DEADLINE NOTICE: ROSEN, A LONGSTANDING LAW FIRM, - GlobeNewswire

Oct 24, 2024
pulisher
Oct 24, 2024

SHAREHOLDER ALERT: Holzer & Holzer, LLC Reminds Investors - GlobeNewswire

Oct 24, 2024
pulisher
Oct 24, 2024

Verve Therapeutics (NASDAQ:VERV) Stock Price Up 7%Still a Buy? - MarketBeat

Oct 24, 2024
pulisher
Oct 23, 2024

Verve Therapeutics, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. October 28, 2024 Deadline to file Lead Plaintiff Motion - ForexTV.com

Oct 23, 2024
pulisher
Oct 23, 2024

Verve Therapeutics, Inc. Investors: Please contact the - GlobeNewswire

Oct 23, 2024
pulisher
Oct 23, 2024

Verve Therapeutics stock plunges as cholesterol-lowering gene-editing treatment faces setback - MSN

Oct 23, 2024
pulisher
Oct 23, 2024

Verve Therapeutics, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before October 28, 2024 to Discuss Your Rights – VERV - ForexTV.com

Oct 23, 2024
pulisher
Oct 23, 2024

Verve Therapeutics Inc Sued for Securities Law ViolationsContact the DJS Law Group to Discuss Your RightsVERV - PR Newswire

Oct 23, 2024
pulisher
Oct 22, 2024

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Verve Therapeutics - AccessWire

Oct 22, 2024
pulisher
Oct 22, 2024

Class Action Filed Against Verve Therapeutics, Inc. (VERV) Seeking Recovery for InvestorsContact Levi & Korsinsky - AccessWire

Oct 22, 2024
pulisher
Oct 22, 2024

VERV FINAL DEADLINE: RLF, RECOGNIZED INVESTOR COUNSEL, Encourages Verve Therapeutics, Inc. - The Bakersfield Californian

Oct 22, 2024
pulisher
Oct 22, 2024

VERV FINAL DEADLINE: RLF, RECOGNIZED INVESTOR COUNSEL, Encourages Verve Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important October 28 Deadline in Securities Class Action Commenced by the Firm – VERV - GlobeNewswire Inc.

Oct 22, 2024
pulisher
Oct 21, 2024

Bragar Eagel & Squire, P.C. Reminds Investors That Class - GlobeNewswire

Oct 21, 2024
pulisher
Oct 21, 2024

Investors in Verve Therapeutics, Inc. Should Contact Levi & Korsinsky Before October 28, 2024 to Discuss Your RightsVERV - AccessWire

Oct 21, 2024
pulisher
Oct 21, 2024

Investors who Lost Money on Verve Therapeutics, Inc. (VERV) Should Contact Levi & Korsinsky About Pending Class ActionVERV - AccessWire

Oct 21, 2024

Finanzdaten der Verve Therapeutics Inc-Aktie (VERV)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Verve Therapeutics Inc-Aktie (VERV) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
Ashe Andrew D.
See Remarks
May 14 '24
Buy
6.26
76,000
475,760
342,509
Nickerson Joan
Chief Administrative Officer
Apr 02 '24
Sale
8.24
1,514
12,475
8,659
Dorval Allison
Chief Financial Officer
Nov 29 '23
Sale
11.45
554
6,343
4,060
$18.98
price up icon 1.80%
$70.68
price down icon 0.42%
$38.38
price up icon 3.49%
$369.83
price up icon 1.48%
$196.58
price up icon 0.88%
$102.64
price up icon 0.27%
Kapitalisierung:     |  Volumen (24h):